Reuters -- Bristol-Myers Squibb Co reported better-than-expected quarterly earnings, helped by strong sales of its Plavix blood clot preventer and HIV drugs, but trimmed its 2010 profit forecast due to costs of U.S. healthcare reform.
Reuters -- Bristol-Myers Squibb Co reported better-than-expected quarterly earnings, helped by strong sales of its Plavix blood clot preventer and HIV drugs, but trimmed its 2010 profit forecast due to costs of U.S. healthcare reform.
